Fehrenbacher et al. also showed that the knockdown of LAMP-1 or LAMP-2 is sufficient to sensitize the cells to siramesine-induced cell death and photooxidation-induced lysosomal destabilization, indicating that lysosome-targeting compounds are promising agents for cancer therapy [172]. This evidence concerns the gene LAMP2 and cancer.